Adult anti-syncytial vaccine protects for 3 seasons, says GSK

The farmaceutical group GSK has recently unveiled promising outcomes from its phase AReSVi-006 trial (Adult Respiratory Syncytial Virus). The study, which assessed the efficacy of a single dose of Arexvy (a recombinant vaccine) against low respiratory disease associated with the pathogen, yielded encouraging results for three complete seasons. The vaccine demonstrated effectiveness in adults aged 60 years and above, including those at elevated risk. The data will be presented at the annual meeting of the American College of Chest Physicians, which is being held under the aegis of the Chest 2024 Annual Meeting. Respiratory syncytial virus (RSV) is a highly prevalent contagious virus that affects the lungs and respiratory tract of approximately 64 million individuals of all ages worldwide annually. In adults aged 60 years or older in high-income countries, it is a significant cause of hospital admission (465,000 cases annually) and mortality (33,000 deaths annually). Should the three-season cumulative efficacy of Rsv be corroborated by long-term follow-up data, the vaccine produced by GSK could have a considerable impact on global public health.